Although mechanistic understanding of the drivers of stemness in mutant-IDH AML are still lacking, these data suggests that leukaemia stemness signatures underscore a potential prognostic biomarker for IDH inhibitor response. This evidence concerns the gene IDH2 and acute myeloid leukemia.